Increased lysophosphatidic acid levels in culprit coronary arteries ofpatients with acute coronary syndrome

Atherosclerosis

Volumn 229, Issue 1, 2013, Pages 192-197

  Dohi, Tomotaka ^a   Miyauchi, Katsumi ^a   Ohkawa, Ryunosuke ^b   Nakamura, Kazuhiro ^b   Kurano, Makoto ^b   Kishimoto, Tatsuya ^c   Yanagisawa, Naotake ^a   Ogita, Manabu ^a   Miyazaki, Tadashi ^a   Nishino, Akihisa ^a   Yaginuma, Kenji ^a   Tamura, Hiroshi ^a   Kojima, Takahiko ^a   Yokoyama, Ken ^a   Kurata, Takeshi ^a   Shimada, Kazunori ^a   Daida, Hiroyuki ^a   Yatomi, Yutaka ^b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Alfresa Pharma Corporation   (Japan)

Author keywords

Acute coronary syndrome; Lysophosphatidic acid; Lysophosphatidylcholine; Plaque instability; Platelet activation

Indexed keywords

ACETYLSALICYLIC ACID; AUTOTAXIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CD40 LIGAND; CLOPIDOGREL; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDYLCHOLINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIAC PATIENT; CARDIOGENIC SHOCK; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY; CROSS-SECTIONAL STUDY; FEMALE; HEART HEMODYNAMICS; HUMAN; INTRAAORTIC BALLOON PUMP; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBECTOMY; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CORONARY THROMBOSIS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIPIDS; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PROSPECTIVE STUDIES;

EID: 84879411971     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.03.038     Document Type: Article

References (35)

1. Siess W., Tigyi G. Thrombogenic and atherogenic activities of lysophosphatidic acid. JCell Biochem 2004, 92:1086-1094.
2. Siess W. Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein. Pathophysiol Haemost Thromb 2006, 35:292-304.
3. Morris A.J., Selim S., Salous A., et al. Blood relatives: dynamic regulation of bioactive lysophosphatidic acid and sphingosine-1-phosphate metabolism in the circulation. Trends Cardiovasc Med 2009, 19:135-140.
4. Siess W. Athero- and thrombogenic actions of lysophosphatidic acid and sphingosine-1-phosphate. Biochim Biophys Acta 2002, 1582:204-215.
5. Schober A., Siess W. Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol 2012, 167:465-482.
6. Aoki J., Taira A., Takanezawa Y., et al. Serum lysophosphatidic acid is produced through diverse phospholipase pathways. JBiol Chem 2002, 277:48737-48744.
7. Bot M., Bot I., Lopez-Vales R., et al. Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation. Am J Pathol 2010, 176:3073-3084.
8. Siess W., Zangl K.J., Essler M., et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci U S A 1999, 96:6931-6936.
9. Smyth S.S., Cheng H.Y., Miriyala S., et al. Roles of lysophosphatidic acid in cardiovascular physiology and disease. Biochim Biophys Acta 2008, 1781:563-570.
10. Schober L.J., Khandoga A.L., Dwivedi S., et al. The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP (4) receptor activation and platelet function in whole blood. JThromb Thrombolysis 2011, 32:158-166.
11. Dohi T., Miyauchi K., Ohkawa R., et al. Increased circulating plasma lysophosphatidic acid in patients with acute coronary syndrome. Clin Chim Acta 2012, 413:207-212.
12. Antman E.M., Hand M., Armstrong P.W., et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 writing group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008, 117:296-329.
13. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Writing Committee to revise the2002 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007, 116:e148-e304.
14. Kishimoto T., Matsuoka T., Imamura S., et al. Anovel colorimetric assay for the determination of lysophosphatidic acid in plasma using an enzymatic cycling method. Clin Chim Acta 2003, 333:59-67.
15. Nakamura K., Kishimoto T., Ohkawa R., et al. Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma invitro: proposal of a plasma sample preparation method for laboratory testing of these lipids. Anal Biochem 2007, 367:20-27.
16. Kishimoto T., Soda Y., Matsuyama Y., et al. An enzymatic assay for lysophosphatidylcholine concentration in human serum and plasma. Clin Biochem 2002, 35:411-416.
17. Nakamura K., Igarashi K., Ide K., et al. Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation. Clin Chim Acta 2008, 388:51-58.
18. Hosogaya S., Yatomi Y., Nakamura K., et al. Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity. Ann Clin Biochem 2008, 45:364-368.
19. Kosaka T., Yamaguchi M., Soda Y., et al. Spectrophotometric assay for serum platelet-activating factor acetylhydrolase activity. Clin Chim Acta 2000, 296:151-161.
20. Bolen A.L., Naren A.P., Yarlagadda S., et al. The phospholipase A1 activity of lysophospholipase A-I links platelet activation to LPA production during blood coagulation. JLipid Res 2011, 52:958-970.
21. Fulkerson Z., Wu T., Sunkara M., et al. Binding of autotaxin to integrins localizes lysophosphatidic acid production to platelets and mammalian cells. JBiol Chem 2011, 286:34654-34663.
22. Hausmann J., Kamtekar S., Christodoulou E., et al. Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol 2011, 18:198-204.
23. Wilensky R.L., Shi Y., Mohler E.R., et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008, 14:1059-1066.
24. Chen C., Ochoa L.N., Kagan A., et al. Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Atherosclerosis 2012, 222:74-83.
25. Zhou Z., Subramanian P., Sevilmis G., et al. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab 2011, 13:592-600.
26. Subramanian P., Karshovska E., Reinhard P., et al. Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation. Circ Res 2010, 107:96-105.
27. Haseruck N., Erl W., Pandey D., et al. The plaque lipid lysophosphatidic acid stimulates platelet activation and platelet-monocyte aggregate formation in whole blood: involvement of P2Y1 and P2Y12 receptors. Blood 2004, 103:2585-2592.
28. Rother E., Brandl R., Baker D.L., et al. Subtype-selective antagonists of lysophosphatidic acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 2003, 108:741-747.
29. Khandoga A.L., Pandey D., Welsch U., et al. GPR92/LPA(5) lysophosphatidate receptor mediates megakaryocytic cell shape change induced by human atherosclerotic plaques. Cardiovasc Res 2011, 90:157-164.
30. Williams J.R., Khandoga A.L., Goyal P., et al. Unique ligand selectivity of the GPR92/LPA5 lysophosphatidate receptor indicates role in human platelet activation. JBiol Chem 2009, 284:17304-17319.
31. Antoniades C., Bakogiannis C., Tousoulis D., et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. JAm Coll Cardiol 2009, 54:669-677.
32. Anand S.X., Viles-Gonzalez J.F., Badimon J.J., et al. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003, 90:377-384.
33. Schonbeck U., Libby P. CD40 signaling and plaque instability. Circ Res 2001, 89:1092-1103.
34. Wang Y., Li L., Tan H.W., et al. Transcoronary concentration gradient of sCD40L and hsCRP in patients with coronary heart disease. Clin Cardiol 2007, 30:86-91.
35. Ko Y.G., Jung J.H., Park S., et al. Inflammatory and vasoactive factors in the aspirate from the culprit coronary artery of patients with acute myocardial infarction. Int J Cardiol 2006, 112:66-71.